Last checked at 
(TIMELINE listing in chronological order events related to the
development of AstraZeneca's COVID-19 vaccine)
(.)
April 30 (Reuters) - AstraZeneca said on Friday its
COVID-19 vaccine contributed $275 million in sales and shaved
three cents per share from its first-quarter earnings.
This marked the first time the Anglo-Swedish drugmaker has
given financial details about the distribution and sales of its
vaccine, which it developed with Oxford University.
Here is a summary of the vaccine's progress since inception:
JANUARY 2020:
A team involving Oxford Vaccine Group and Jenner Institute
begins developing a vaccine to prevent COVID-19.
MARCH 2020:
Oxford University researchers begin screening healthy
volunteers, aged 18-55, for a ChAdOx1 nCoV-19 vaccine trial.
APRIL 2020:
Human trials begin. AstraZeneca joins forces with Oxford on
development and potential distribution of the vaccine candidate.
MAY 2020:
AstraZeneca and Oxford start recruiting volunteers for a
much larger human trial in the UK.
JULY 2020:
Initial safety data showed vaccine was safe and produced an
immune response.
AUGUST 2020:
Vaccine candidate begins late-stage study in the United
States.
SEPTEMBER 2020:
AstraZeneca suspends global trials due to an unexplained
illness in a study participant.
AstraZeneca resumes UK trials.
Oxford/AstraZeneca begin submitting data to the UK regulator
under rolling review process.
OCTOBER 2020:
EU launches real-time review of vaccine.
United States restarts trial, the last one to do so after
other regions.
NOVEMBER 2020:
AstraZeneca confirms that UK regulator has started an
accelerated review of vaccine.
Interim late-stage data from UK, South Africa trials
released.
On average it prevented 70% of COVID-19 cases in late-stage
trials in Britain and Brazil.
The success rate rose to 90% in a group of participants who
accidentally received a half dose followed by a full dose.
The efficacy was 62% if the full dose was given twice, as it
was for most study participants.
DECEMBER 2020:
Britain approves the shot in a first for COVID-19 vaccines
in the West. Regulators said that the higher efficacy seen in
the half-dose/full-dose cohort was likely a result of a longer
gap between doses, rather than the amount of vaccine given.
JANUARY 2021:
India approves Serum's vaccine in early January.
Europe gives vaccine green light late January.
FEBRUARY 2021:
World Health Organisation gives vaccine the go-ahead.
MARCH 2021:
AstraZeneca cut first-quarter supply forecast to the EU due
to export constraints.
Austria halts use of one batch of vaccine after reports of
cases of blood clots in Nordics.
More than a dozen European countries, including Germany and
France, halt use of the vaccine.
European regulators and WHO back its safety in mid-March.
In late March, interim data from late-stage trials in U.S.,
Peru, Chile shows vaccine is 79% effective.
The U.S. National Institute of Allergy and Infectious
Diseases said AstraZeneca may have included outdated information
from the trial, providing an incomplete view of efficacy data.
Norway keeps the vaccine on hold for another three weeks.
Canada pauses use of the vaccine for under-55s.
APRIL 2021:
UK regulator found total of 30 cases of blood clot events
after AstraZeneca vaccine use. EU drug regulator finds link
between vaccine and blood clots, but benefits outweigh risks
WHO reiterates AstraZeneca benefits outweigh risks.
Oxford pauses vaccine study in children.
Britain advises alternative to the vaccine for under-30s.
EU drug regulator says up to countries to decide how to
handle AstraZeneca distribution.
Italy, Britain suggest age limits but still recommend it.
Australia reports first blood clot death 'likely' linked to
the vaccine. Backs Pfizer over AstraZeneca for under-50s.
Denmark ditches AstraZeneca's COVID-19 shot.
Canadian panel expands use of AstraZeneca doses.
Chilean AstraZeneca trial saw no cases of blood clots.
EU sues AstraZeneca over breach of COVID-19 vaccine supply
contract, demands immediate access to UK-made vaccines
(Reporting by Pushkala Aripaka, Yadarisa Shabong and Aby Jose
Koilparambil in Bengaluru; Editing by Hugh Lawson and Alexander
Smith)
